RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar Sells 3,782 Shares

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,782 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now directly owns 10,902 shares in the company, valued at $500,183.76. This trade represents a 25.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

RxSight Trading Down 0.7 %

NASDAQ RXST traded down $0.32 on Tuesday, hitting $46.06. 229,941 shares of the company were exchanged, compared to its average volume of 488,755. The firm has a 50 day moving average of $49.20 and a two-hundred day moving average of $52.57. The company has a market cap of $1.86 billion, a P/E ratio of -55.49 and a beta of 1.19. RxSight, Inc. has a 1-year low of $28.88 and a 1-year high of $66.54.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Wells Fargo & Company lowered their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight presently has a consensus rating of “Buy” and a consensus price target of $61.63.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RXST. CWM LLC lifted its position in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the period. Nisa Investment Advisors LLC lifted its position in RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after purchasing an additional 521 shares during the period. Quarry LP lifted its position in RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd acquired a new position in RxSight during the 3rd quarter valued at about $34,000. Finally, Quest Partners LLC acquired a new stake in shares of RxSight in the 2nd quarter valued at approximately $41,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.